Synthesis and anti-leukaemic activity of pyrrolo [3,2,1-hi] Synthesis and anti-leukaemic activity of pyrrolo[3,2,1-hi]indole-1,2-diones, pyrrolo[3,2,1-ij]quinoline-1,2-diones and other polycyclic isatin derivatives
Introduction
Isatin has been derivatised at the N1, C2, C3, C5, C6 and C7 positions in an attempt to increase its biological activity, in particular its cytotoxicity.
1 N-Substituted arylalkyl isatin derivatives of type I (Fig. 1) showed excellent potency but it was thought that restraining conformational mobility in the substituent would further improve activities in these isatins, based on improvements in the activity of other anti-cancer agents through conformational restrictions. 2 In order to achieve this, we initially considered target systems with a 5-or 6-membered ring present involving N1 and C7 in the isatin (systems of type II or III respectively; Fig. 1 ). In these systems the bromo substituent would be replaced by a similarly hydrophobic methylene or methine group and rotation about the N-αC bond would be restricted. Systems of type II and III correspond to pyrrolo[3,2,1-hi]indole-1,2-dione (6,5,5-tricyclic) and pyrrolo[3,2,1-ij]quinoline-1,2-dione (6,5,6-tricyclic) derivatives respectively. To facilitate comparison between previously reported N-alkylisatins 1c and the new tricyclic isatins, a bromo substituent (R) was to be incorporated to improve cytotoxicity, 1b, 3 and R 1 was to be H, alkyl, or aryl. Later target systems envisaged incorporating elements of the aryl groups in I in further fused rings to afford targets IV(pyrrolo[3,2,1-de]acridine-1,2-diones) and V (pyrrolo[3,2,1-de]phenanthridine-and benzo [j] or [l] pyrrolo[3,2,1-de]phenanthridine-4,5-diones) (Fig.  2) . 
A R T I C L E I N F O A B S T R A C T
To further expand the structure-cytotoxic activity relationships of isatin derivatives and to reduce flexibility in substituent groups at nitrogen, 20 analogues incorporating a ring system between the N1 and C7 atoms of isatin were prepared using a variety of synthetic strategies. This yielded pyrroloindole-, pyrroloquinoline-, pyrroloacridine-, pyrrolophenanthridine-and benzopyrrolophenanthridine-based systems with embedded isatin moieties, the latter possessing a novel carbon skeleton. These compounds were subsequently assessed for their in vitro cytotoxicity against human U937 lymphoma cells, with the brominated pyrroloacridine dione 27 showing the most promising activity (IC 50 3.01 μM) after 24 h.
2009 Elsevier Ltd. All rights reserved. known examples of pyrrolo[3,2,1-hi]indole-1,2-diones. 4 This may be attributed to the fact that 6,5,5-fused indole ring systems are highly strained. 5 Similarly, the pyrrolo[3,2,1-ij]quinoline nucleus is established 6 and many compounds containing this scaffold have also been reported to exhibit a broad spectrum of biological activities including analgesic, anti-pyretic, antiinflammatory, 6a anti-hyperlipidemic, anti-hypertensive, 7 anti-epileptic, anti-obesity 8 and anti-cancer 9 activities. Approximately 50 of the analogous isatin-based pyrrolo[3,2,1-ij]quinoline-1,2-diones have been reported in the literature to date. Structures of type IV 10 and the ABCDE ring system in type V 11 are rare in the literature, while the ABCDF ring system in type V represents a new heterocyclic scaffold. The ABCD ring system in type V is well known, however, and is present in many natural products including the Amaryllidaceae alkaloids. 6a, 12 Two general approaches were considered for accessing the target systems. The first of these (route (i)) was based on constructing the 5-membered dione ring B from an amine precursor while the second (route (ii)), involved C7-N annulation from an isatin precursor (Fig. 3) . The outcomes from these two approaches, along with the cytotoxic evaluation of the products, are now reported in this paper. 
Results and discussion

Pyrroloindole-dione derivatives II
The Stolle isatin synthesis (route (i), Fig. 3 ), which involves a crucial intramolecular Friedel-Crafts acylation in the penultimate ring forming step, was attempted to access these derivatives with a 5-membered ring fusion. This synthetic approach has been employed to prepare a variety of isatins 13 including N-aryl and polycyclic isatins. 14 In 1979, Welstead Jr. et al. reported the first synthesis of the tricyclic isatin 2 from indoline (1) in 8% overall yield using the Stolle procedure. 4a The yield was reportedly increased to 22% in 1996 by Norman et al. 15 In the current work, our attempts to synthesise pyrrolo[3,2,1-hi]indole-1,2-diones using free radical cyclisations and assorted heteroannulations were unsuccessful, however, the synthetic method based on the work by Norman et al. provided the desired tricyclic isatin 2, albeit in low yield (Scheme 1). Subsequent bromination of 2 proceeded smoothly to afford 3 in moderate yield. Because of difficulties encountered in the cyclisation step, the synthesis of ring C-substituted pyrrolo[3,2,1-hi]indole-1,2-diones was not pursued. Semi-empirical level computational studies (AM1; Materials Studio 4.4) on 2 and its analogue with a C4-C5 double bond confirmed the expected significant strain in these compounds with positive heats of formation values (ΔH f 10.9 and 43.2 kcal/mol respectively).
Pyrroloquinoline-dione derivatives III
Via route(i)
Pyrrolo[3,2,1-ij]quinoline-1,2-dione (5) was prepared by cyclising 1,2,3,4-tetrahydroquinoline (4) following a similar method described for the 5-membered analogue 2. The compound was subsequently brominated to afford 6 in high yield (Scheme 1). To further investigate the cytotoxic SAR of the 6,5,6-fused tricyclic isatins, structures incorporating N-arylalkyl substituents were desired. The selective addition of an aryl substituent to the cyclised isatin 5 was expected to be difficult, hence, the required N-arylalkyl moiety would need to be incorporated into the structure prior to cyclisation. Reacting quinoline (7), with phenylmagnesium bromide (PhMgBr) formed 2-phenyl-1,2-dihydroquinoline (8) (Scheme 2). Due to the air-sensitivity and instability of 1,2-dihydroquinolines, 16 8 was used in further reactions immediately after its preparation and purification was not attempted. Upon treatment with oxalyl chloride and AlCl 3 , 8 was cyclised to form the novel tricyclic isatin 9 in trace amounts, which may be explained in part by the use of crude 2-phenyl-1,2-dihydroquinoline (8) . The structure of 9 was confirmed through the 13 C NMR spectrum, which displayed two diagnostic carbonyl signals at 157.4 and 182.4 ppm, indicative of C2 and C1 respectively. Due to the low yield of 9 and the likelihood of bromine preferentially attacking the alkene rather than the aromatic ring, synthesis of the 8-bromo analogue was not attempted.
To prepare the saturated analogue of tricyclic isatin 9, the dihydroquinoline 8 was reduced to 2-phenyl-1,2,3,4-tetrahydroquinoline (10), followed by treatment with oxalyl chloride and AlCl 3 to afford the tricyclic isatin 11 (Scheme 2), which was also indicated by the appearance of two carbonyl signals at 156.8 and 183.6 ppm in the 13 C NMR spectrum. The multiplicities and chemical shifts ascribed to the aromatic protons in the 1 H NMR spectrum also pointed to cyclisation having occurred to the activated C8 position in the tetrahydroquinoline nucleus rather than to the ortho-position in the pendant phenyl group. The tricyclic isatin 11 was then exposed to Br 2 to yield the racemic brominated tricyclic isatin 12 (Scheme 2). 
II -V
Via route (ii)
Many intramolecular Heck reactions have previously been applied to indoles to form tricyclic indoles. 5, 17 The formation of a 1,7-annulated isatin with an eight-membered ring through an intramolecular Heck reaction has also been reported, 18 however, the reaction has not been used to form 1,7-annulated isatins containing smaller ring sizes. Subjection of N-allyl-7-bromoisatin (13) to Heck conditions similar to those reported by Black et al. 5 provided the isomeric 6-endo-trig products 14 and 15 in a 3:1 ratio (Scheme 3). These products could be isolated by preparative TLC.
To obtain the 8-bromo analogues of 14 and 15 for cytotoxicity testing, N-allyl-5,7-dibromoisatin (16) was synthesised using the same conditions as for 13. Subsequent exposure of 16 to intramolecular Heck conditions gave the brominated tricyclic isatins 17 and 18 in moderate yield (Scheme 3). Analysis by 1 H NMR spectroscopy revealed the 4H and 6H isomers (17 and 18) had formed in a 3:2 ratio, with the 4H isomer 17 again being the predominant. The Heck reaction was also applied to other N-allylated isatins to further explore the synthesis and cytotoxicity of 6,5,6-tricyclics with phenyl or methyl substituents in ring C (Scheme 4). Thus, 7-bromoisatin (19) was reacted with crotyl bromide to yield 20, followed by an intramolecular Heck reaction to yield the tricyclic isatin 21, which was formed exclusively as determined by 1D and 2D NMR spectroscopy. Due to the low yield of 21, synthesis of the analogous 8-bromo analogue was not attempted. 7-Bromoisatin (19) was also reacted with cinnamyl bromide to provide 22 and a subsequent intramolecular Heck reaction gave 23 (Scheme 4). 
Pyrroloacridine-, pyrrolophenanthridine-and benzopyrrolophenanthridine-dione derivatives IV-V
In order to further explore the utility of the isatin scaffold for the development of novel cytotoxins and to incorporate the N-benzylic substituent moiety into a fused aromatic ring, it was decided to extend the quinoline nucleus to systems containing benzo or naphtho rings fused onto the heterocyclic ring of quinoline (Fig. 2) . Specific targets included pyrroloacridinediones 26 and 27, which incorporated the cytotoxic acridine 19 and isatin moieties, as well as the pyrrolophenanthridine-diones 30 and 31 together with the benzopyrrolophenanthridine-dione derivative 36, and the isomeric systems in 40 and 41.
One compact route to the acridine-and phenanthridinebased isatins applies the Stolle isatin method (route (i), Fig. 3 ) to dihydroacridine 25 and dihydrophenanthridine 29, which can be readily accessed in turn from acridine 24 or phenanthridrine 28 respectively, by reduction 20 with NaCNBH 3 (Scheme 5). It has been shown that the addition of a base and 4-(dimethylamino)pyridine (DMAP) to 29 was necessary to achieve good yields of amide derivatives. 21 In this case, the addition of N,N-diisopropylethylamine (DIPEA) and a catalytic amount of DMAP was employed to facilitate the formation of the oxamide intermediate, before being cyclised directly with AlCl 3 to yield 30. The acridine-based isatin 26 was able to be prepared without the addition of DIPEA and DMAP in the intermediate amide formation step. Bromination of 26 and 30 proceeded smoothly in glacial AcOH to yield 27 and 31 (Scheme 5). The 1 H NMR spectrum revealed the absence of the H4 and H2 protons, respectively, in these bromo derivatives. An alternative approach (route (ii), Fig. 3 ) which incorporated Pd-mediated intramolecular cyclisation 6a was used to prepare the other benzo-fused pyrrolophenanthridine targets. These phenanthridine-embedded isatins could be prepared through the Pd-catalysed biaryl intramolecular coupling 22 of N-arylalkylisatins such as 7-iodo-N-(1-naphthylmethyl)isatin (33) and 7-iodo-N-(2-naphthylmethyl)isatin (37). The precursor 33 was readily accessed by N-alkylation of 32, and the reactive C3 carbonyl 12, 22 was then protected as a cyclic ketal to afford 34 (Scheme 6).
Reaction of the isatin 34 with Pd(OAc) 2 enabled an intramolecular biaryl coupling to take place with the possibility of two regioisomers being formed. The 1 H NMR spectral data indicated the isomer produced in high yield was the benzopyrrolophenanthridine 35. The aromatic proton signals for H9' (7.56 ppm) and H10' (7.50 ppm) in 35 were observed as triplets which were coupled to one another.
Under acidic conditions the ketal moiety in 35 was hydrolysed to yield the target 36, a new heterocyclic ring system, as a dark red powder (Scheme 6). The red colour of the compound is strong evidence that the ketal had been destroyed and that the C4 carbonyl, an important element in the chromophore of the isatin core, had been restored. Bromination of 36 was unsuccessful due to the poor solubility of the substrate in organic solvents. The isomeric benzopyrrolophenanthridine dione 40 could also be accessed by biaryl coupling using 7-iodo-N-(2-naphthylmethyl)isatin (37) (Scheme 7). Again, the N-naphthylmethylisatin 37 was subjected to Dean-Stark conditions to protect the ketone as a cyclic ketal prior to biaryl coupling. As with the related compound 36, the intramolecular biaryl coupling of 38 could lead to two regioisomers. A pair of coupled doublets (H8' and H9' at 7.21 and 7.74 ppm respectively) and two triplet signals coupled to each other (H11' and H12' at 7.50 and 7.56 ppm respectively) were observed in the 1 H NMR spectrum, which is consistent with the exclusive formation of isomer 39 (Scheme 7). The regioselectivity of this reaction is in accordance with results for similar pyrrolophenanthridine reactions reported by Torres et al. 
Biological results
Preliminary cytotoxicity testing of the 20 tricyclic/polycyclic isatins was carried out on the U937 human histiocytic lymphoma cell line using the CellTiter 96 ® AQ ueous One Solution Cell Proliferation Assay (MTS assay) ( Table 1 ). This cell line has been utilised previously within our research group 1b-d to screen the in vitro cytotoxicity of isatin derivatives. values were calculated from sigmoidal dose-response curves (variable slope) generated using GraphPad Prism 5.00 (GraphPad Software Inc., San Diego, CA, USA). Values are the mean of at least two independent experiments performed in triplicate ± SEM.
The 6,5,5-fused tricyclic isatin, pyrrolo[3,2,1-hi]indole-1,2-dione (2) was inactive against U937 cells with an IC 50 value of > 577 µM (beyond testing limits), while the brominated analogue 3 displayed an IC 50 value of 111 µM, a 5-fold increase in cytotoxicity. However, isatin and 5-bromoisatin have IC 50 values of 565 µM and 64.5 µM respectively, against the same cell line, 1b establishing that the tricyclic analogues 2 and 3 are less active than the parent isatin molecules. Conversely, the 6,5,6-fused tricyclic isatin, pyrrolo[3,2,1-ij]quinoline-1,2-dione (5), displayed at least a 2-fold increase in cytotoxicity compared to 2 and is more active than the parent molecule, isatin. The brominated derivative 6 exhibited a 33-fold increase in activity when compared to 5. A similar pattern was observed for polycyclic compounds where the brominated derivatives displayed greater cytotoxicity (up to 2.4 times) than their parent molecules (i.e. 27 vs. 26; 31 vs. 30; 41 vs. 40).
The introduction of a double bond into compounds 14 and 15 led to an approximate 6-fold increase in cytotoxicity when compared to the parent molecule 5. The inclusion of a phenyl substituent at the C6 position in 23 resulted in decreased cytotoxicity compared to the parent compound 15, while a methyl substituent at C6 in 21 increased activity compared to compound 15.
Although more than one structural change was made in compound 12 (IC 50 15.3 µM), it is apparent that restricting rotation in the N-benzyl group through ring formation in this way had a detrimental effect on cytotoxic potency in comparison to N-benzyl-5,7-dibromoisatin (IC 50 1.14 µM; U937).
1c Similarly, incorporation of a methylene group and part of the naphthyl ring in the ring fusion as in compound 41 (IC 50 18.2 µM) resulted in a deterioration of activity compared to 5,7-dibromo-N-(2-naphthylmethyl)isatin (IC 50 0.74 µM; U937). The addition of the extra ring system in 40 increased the cytotoxicity 2-fold compared to 30, while the introduction of an additional ring in derivative 36 decreased cytotoxic activity at least 2.5-fold compared to 30. The pyrroloacridine 26 was greater than 6-fold more cytotoxic than the pyrrolophenanthridine 30 and both acridines (26 and 27) are highly cytotoxic (IC 50 < 10 µM). These two compounds were significantly more cytotoxic than any of the tricyclic derivatives shown in Table 1 with the most active compound (27) having an IC 50 value of 3.01 µM against U937 cells after 24 h, which is more potent than the anti-cancer drug vinblastine against the same cell line (Table 1) .
Conclusions
The successful synthesis of two pyrrolo[3,2,1-hi]indole-1,2-diones, together with eleven pyrrolo[3,2,1-ij]quinoline-1,2-diones, two pyrrolo[3,2,1-de]acridine-1,2-diones and two pyrrolo[3,2,1-de]phenanthridine-4,5-diones via the Stolle isatin synthesis or intramolecular Heck reactions is described. Three other benzo[j]or[l]pyrrolo[3,2,1-de]phenanthridine-4,5-diones, the last system being novel, were also prepared utilizing Pd-mediated intramolecular biaryl coupling methodology from a pre-formed substituted isatin.
In vitro toxicity of the synthsised compounds against U937 cells was assessed and generally, the order of cytotoxicity for the compounds described was pyrroloacridines > (benzo)pyrrolophenanthridines > pyrrolo[3,2,1-ij]quinoline-1,2-diones > pyrrolo[3,2,1-hi]indole-1,2-diones. Bromination at the C5 position of the isatin nucleus increased cytotoxicity relative to the non-brominated analogues in all cases by 2 to 33-fold, similar to previously reported literature.
1a, b The fused acridine-isatin derivative 27 was identified as a new cytotoxic structural lead for potential future development. 
General
Isatin, 1,2,3,4-tetrahydroquinoline, phenanthridine and acridine were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). DCM refers to dichloromethane; PS refers to petroleum spirit (b.p. 40-60 °C). Celite (Celite 545, particle size 0.02-0.1 mm, Merck) was used to remove metal catalysts from reaction mixtures. Flash column chromatography was performed on silica gel 60 (230-400 mesh). Melting points were obtained using a Reichert melting point apparatus and are uncorrected. Geometry optimisation (ΔH f ) of tricyclic isatins was performed using VAMP at semi-empirical level (AM1) on Materials Studio 4.4 (Accelrys Inc., San Diego, CA, USA). Nuclear magnetic resonance (NMR) spectra were acquired on a Varian Unity 300 MHz spectrometer or Varian Inova 500 spectrometer. The symbol † denotes coincident peaks. Low resolution electron ionisation mass spectra (LREI-MS) were obtained using a Shimadzu QP5050 spectrometer; high resolution electron ionisation mass spectra (HREI-MS) were obtained using a Fisons/VG Autospec spectrometer; high resolution electrospray ionisation spectra (HRESI-MS) were obtained using a Waters Q-TOF Ultima spectrometer.
Synthesis
4,5-Dihydropyrrolo[3,2,1-hi]indole-1,2-dione (2)
The compound was prepared according to the method of Norman et al. 15 
7-Bromo-4,5-dihydropyrrolo[3,2,1-hi]indole-1,2-dione (3)
According to the method of Vine et al., 1b the cyclised isatin 2 (100 mg, 577 µmol) was dissolved in 95% EtOH (4 mL) and heated to 75 ºC. Br 2 (276 mg, 88.7 µL, 1.73 mmol) was added drop wise while the solution was still hot. The reaction mixture was then cooled on ice, filtered and concentrated. The resulting solid was purified by flash chromatography (100% DCM) to yield 3 as dark red crystals (47.8 mg, 33%), m.p. 162-164 °C.
1 H NMR (DMSO-d 6 , 500 MHz): δ 3.38 (t, J = 7.5 Hz, 2H), 4.07 (t, J = 7.5 Hz, 2H), 7.49 (s, 1H), 7.66 (s, 1H). 
8-Bromo-5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (6)
The compound was prepared according to the method for 3 using the isatin 
4-Phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (9)
Dihydroquinoline 8 (1.04 g, 5.02 mmol) in anhydrous THF (6 mL) was added portion wise over 30 min to a refluxing solution of oxalyl chloride (1.27 g, 873 L, 10.0 mmol) in anhydrous THF (4 mL). The reaction mixture was heated at reflux for 3.5 h before the solvent was removed by rotary evaporation. The dark residue was dissolved in anhydrous CHCl 3 (30 mL) and heated at reflux. AlCl 3 (2.01 g, 15.1 mmol) was added portion wise over 5 h and the solution was heated at reflux for a further 18 h. The solvent was once again removed by rotary evaporation, the residue was cooled on ice, concentrated HCl (10 mL) was added, followed by H 2 O (10 mL) and CHCl 3 (50 mL). The phases were separated and the organic layer was washed with H 2 O (2 × 50 mL), dried over MgSO 4 , filtered and the solvent removed by rotary evaporation. The resulting solid was purified by flash chromatography (100% DCM) to yield 9 as dark red crystals 
5,6-Dihydro-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (11)
The compound was prepared according to the method for 9 using 10 (2.00 g, 9.56 mmol) and oxalyl chloride (2.42 g, 
8-Bromo-5,6-dihydro-4-phenyl-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (12)
The compound was prepared according to the method for 6 using the isatin 11 ( 
1-Allyl-7-bromo-1H-indole-2,3-dione (13)
A mixture of 7-bromoisatin (19) (250 mg, 1.11 mmol) and NaH (62.3 mg, 1.55 mmol) was dissolved in anhydrous DMF (6 mL) and stirred at RT for 20 min before the addition of KI (37.2 mg, 222 mol) and allyl bromide (295 mg, 211 L, 2.44 mmol). The reaction mixture was heated at 60 °C and stirred at this temperature for 18 h. After cooling, EtOAc (25 mL) was added and the resulting solution was extracted with 0.5 M HCl (25 mL), followed by brine (25 mL). The orange organic layer was dried over MgSO 4 and the solvent was removed by rotary evaporation to yield a sticky red residue. The resulting solid was purified by flash chromatography (100% DCM) to yield 13 as orange crystals (236 mg, 81%), m.p. 112-114 °C. 
4H-Pyrrolo[3,2,1-ij]quinoline-1,2-dione (14) and 6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (15)
The isatin 13 (150 mg, 564 mol), TBACl (157 mg, 564 mol), K 2 CO 3 (234 mg, 1.69 mmol) and Pd(OAc) 2 (12.7 mg, 56.4 mol) were dissolved in anhydrous DMF (7 mL) and heated at 85 °C for 2 h. Upon cooling, DCM (50 mL) was added and the solution was extracted with H 2 O (3 × 15 mL) and brine (1 × 15 mL). The organic layer was dried over MgSO 4 , the suspension filtered and the solvent removed by rotary evaporation. The resulting solid was purified by flash chromatography and preparative TLC (100% DCM) to yield 14 (41.1 mg, 39%) and 15 (13. 6 mg, 13%) 
1-Allyl-5,7-dibromo-1H-indole-2,3-dione (16)
The compound was prepared according to the method for 13 using 5,7-dibromoisatin (1.50 g, 4.92 mmol), NaH (165 mg, 6.89 mmol), KI (163 mg, 984 mol) and allyl bromide (1. 31 
8-Bromo-4H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (17) and 8-bromo-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (18)
These compounds were prepared according to the method for 14 and 15 using the isatin 16 (150 mg, 435 mol), TBACl (121 mg, 435 mol), K 2 CO 3 (181 mg, 1.31 mmol) and Pd(OAc) 2 (9.80 mg, 43.5 mol) as starting materials. The resulting solid was purified by flash chromatography (CHCl 3 /PS, 2:1) and preparative TLC (100% DCM) to yield 17 (33.4 mg, 29%) and 18 (22.4 
7-Bromo-1H-indole-2,3-dione (19)
Chloral hydrate (5.01 g, 30.2 mmol) and Na 2 SO 4 (35.0 g, 246 mmol) were dissolved in H 2 O (70 mL) in a 300 mL beaker and heated to 35 °C. 2-Bromoaniline (4.75 g, 3.12 mL, 27.6 mmol) in H 2 O (20 mL) and concentrated HCl (3 mL) were warmed and added to the reaction mixture. Hydroxylamine HCl (6.10 g, 87.8 mmol) in H 2 O (27.5 mL) was warmed and added before the mixture was heated at 85 °C for 3 h. The mixture was cooled, filtered and washed with H 2 O (100 mL) to yield the intermediate (5.75 g, 86%) as a fluffy light brown powder. Concentrated H 2 SO 4 (100 mL) was heated in a 1 L beaker to 60 °C. The intermediate was added in portions over 15 min so the temperature did not exceed 65 °C. The reaction mixture was then heated at 80 °C for 8 15 min before being poured into ice (500 mL). 
(E)-7-Bromo-1-(but-2-enyl)-1H-indole-2,3-dione (20)
The compound was prepared according to the method for 13 using 7-bromoisatin (19) (500 mg 
6-Methyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (21)
The compound was prepared according to the method for 14 and 15 using the isatin 20 (161 mg, 575 mol), K 2 CO 3 (239 mg, 1.73 mmol), TBACl (160 mg, 575 mol) and Pd(OAc) 2 (12.9 mg, 57. 
(E)-7-Bromo-1-(3-phenyl-allyl)-1H-indole-2,3-dione (22)
The compound was prepared according to the method for 13 using 7-bromoisatin (19) (751 mg, 3.33 mmol), NaH (186 mg, 4.66 mmol), KI (111 mg, 670 mol) and cinnamyl bromide (1.45 g, 1.09 mL, 7.33 mmol) as starting materials. The resulting solid was purified by flash chromatography (100% DCM) to yield 22 as an orange powder (551 mg, 48%), m.p. 149-151 °C. 
6-Phenyl-6H-pyrrolo[3,2,1-ij]quinoline-1,2-dione (23)
The compound was prepared according to the method for 14 and 15 using the isatin 22 (130 mg, 380 mol), K 2 CO 3 (158 mg, 1.14 mmol), TBACl (106 mg, 380 mol) and Pd(OAc) 2 
9,10-Dihydroacridine (25)
A mixture of acridine (24) (10.0 g, 55.8 mmol) and AcOH (6.01 g, 5.73 mL, 100 mmol) were added to absolute EtOH (100 mL) and heated at reflux for 30 min before the addition of NaCNBH 3 (6.66 g, 106 mmol). The solution was heated at reflux for a further 1.5 h, cooled and the solvent removed by rotary evaporation. The white residue was basified with aqueous NH 3 (200 mL) and extracted with Et 2 O (3 × 100 mL). The organic extract was evaporated and the white precipitate was recrystallised from 95% EtOH to yield 25 as cream coloured needles (4.76 g, 47%), m.p. 171-172 °C (lit. 
6H-Pyrrolo[3,2,1-de]acridine-1,2-dione (26)
The compound was prepared according to the method for 9 using 9,10-dihydroacridine (25) (4.50 g, 24.8 mmol) and oxalyl chloride (6.30 g, 4.33 mL, 49.6 mmol) as starting materials. The 
4-Bromo-6H-pyrrolo[3,2,1-de]acridine-1,2-dione (27)
The compound was prepared according to the method for 6 using 26 (100 mg, 425 mol), glacial AcOH (5 mL) and Br 2 (205 mg, 65.9 L, 1.28 mmol) as starting materials. The resulting solid was purified by flash chromatography (100% CHCl 3 ) to yield 27 as a dark red powder (54. 
5,6-Dihydrophenanthridine (29)
The compound was prepared according to the method for 25 using phenanthridine (28) (5.00 g, 27.9 mmol), AcOH (1.68 g, 1.60 mL, 27.9 mmol) and NaCNBH 3 (3.33 g, 53.1 mmol) as the starting materials. The crude white precipitate was recrystallised 9 from 95% EtOH to yield 29 as yellow crystals (3.89 g, 77%) 
7H-Pyrrolo[3,2,1-de]phenanthridine-4,5-dione (30)
A mixture of 5,6-dihydrophenanthridine (29) (500 mg, 2.76 mmol), oxalyl chloride (701 mg, 482 L, 5.52 mmol), DMAP (33.7 mg, 276 mol) and DIPEA (357 mg, 480 L, 2.76 mmol) was dissolved in anhydrous THF (10 mL) and heated at reflux for 3.5 h. The solution was evaporated and the residue was dissolved in anhydrous CHCl 3 (40 mL) and heated at reflux. AlCl 3 (1.10 g, 8.28 mmol) was added portion wise over 30 min and the solution was heated at reflux for a further 1.5 h. Upon cooling, the solution was extracted with H 2 O (2 × 25 mL) and brine (1 × 25 mL). The organic extract was dried over MgSO 4, filtered and evaporated. The resulting solid was purified using flash chromatography (100% DCM) to yield 30 as dark red crystals (100 mg, 15%), m. 
2-Bromo-7H-pyrrolo[3,2,1-de]phenanthridine-4,5-dione (31)
The compound was prepared according to the method for 6 using 30 (84.0 mg, 357 mol), glacial AcOH (5 mL) and Br 2 (171 mg, 55.0 L, 1.07 mmol) as starting materials. The resulting solid was purified by flash chromatography (100% CHCl 3 
7-Iodo-1H-indole-2,3-dione (32)
The compound was prepared according to the method for 19 using chloral hydrate (6.67 g, 40.3 mmol), Na 2 SO 4 (46.2 g, 325 mmol), 2-iodoaniline (8.00 g, 36.5 mmol) and hydroxylamine HCl (8. 
7-Iodo-1-(naphthalen-1-ylmethyl)-1H-indole-2,3-dione (33)
This compound was prepared according to the method for 13 using 32 (6.00 g, 22.0 mmol), NaH (739 mg, 30.8 mmol), KI (730 mg, 4.40 mmol) and 1-(chloromethyl)naphthalene (8.11 g, 6.87 mL, 48.4 mmol) as starting materials. The resulting solid was purified by flash chromatography (100% CHCl 3 ) to yield 33 as a red powder (5.29 g, 58%) , m.p. 177-178 °C, R f 0. (34) According to the method of Ribeiro et al., 34 the isatin 33 (4.96 g, 12.0 mmol), ethylene glycol (14.9 g, 13.4 mL, 240 mmol) and PTSA (496 mg, 10% of starting material weight) were dissolved in PhMe (40 mL) and heated at reflux under Dean-Stark conditions for 24 h. No evidence of product had formed so more ethylene glycol was added (7.45 g, 6.70 mL, 120 mmol) and the solution was heated at reflux for a further 24 h before the solvent was removed by rotary evaporation. The resulting solid was purified by flash chromatography (100% DCM) to yield 34 as a beige powder (4.14 g, 75%), m.p. 236-238 °C.
1 H NMR (CDCl 3 , 500 MHz): 
7-Iodo-1-(naphthalen-2-ylmethyl)-1H-indole-2,3-dione (37)
The compound was prepared according to the method for 13 using 32 (2.50 g, 9.16 mmol), NaH (307 mg, 12.8 mmol), KI (304 mg, 1.83 mmol) and 2-(bromomethyl)naphthalene (3.03 g, 13.7 mmol) as starting materials. The resulting solid was purified by flash chromatography (100% CHCl 3 ) to yield 37 as red/brown crystals ( 1.37 g, 36%) 
7'-Iodo-1'-(naphthalen-2-ylmethyl)spiro[[1,3]-dioxolane-2,3'-indolin]-2'-one (38)
The compound was prepared according to the method for 34 using the isatin 37 (1.10 g, 2.66 mmol), ethylene glycol (4.95 g, 4.45 mL, 79.8 mmol) and PTSA (110 mg, 10% of starting material weight) as starting materials. The resulting solid was purified by flash chromatography (100% DCM) to yield 38 as a beige powder (1.12 g, 92%), m.p. 156-158 °C. 
Spiro[benzo[l]pyrrolo[3,2,1-de]phenanthridine-4,2'-[1,3]dioxolan]-5(7H)-one (39)
The compound was prepared according to the method for 35 using the ketal 38 (1.00 g, 2.19 mmol), Pd(OAc) 2 (49.2 mg, 219 µmol), TBAB (777 mg, 2.41 mmol) and NaOAc (902 mg, 11.0 mmol) as starting materials. The resulting solid was purified using flash chromatography (100% CHCl 3 ) to yield 39 as a beige powder (485 mg, 67%), m.p. 161-163 °C.
7H-Benzo[l]pyrrolo[3,2,1-de]phenanthridine-4,5-dione (40)
The compound was prepared according to the method for 36 using the cyclised ketal 39 (420 mg, 1. 
Cytotoxicity Testing
Human U937 histiocytic lymphoma cells were obtained from the American Type Culture Collection (ATCC, VA, USA). Cells were routinely maintained in RPMI-1640 medium, containing 2 mM L-glutamine, 5.6 % (2 g/L) sodium bicarbonate and 5 % fetal calf serum (at 37 °C, 95 % humidified atmosphere and 5 % CO 2 ). Cytotoxicity of the isatin derivatives was determined using the CellTiter 96 ® AQ ueous One Solution Cell Proliferation Assay (MTS assay) (Promega Co., Madison, WI, USA) as described previously. 1c The concentration required to inhibit 50 % of the metabolic activity of the cell population (IC 50 ) was calculated from sigmoidal dose-response curves using GraphPad Prism 5.00 (GraphPad Software Inc., San Diego, CA, USA) from at least two independent experiments performed in triplicate.
